BioBridge®Collagen Matrix

is a novel nanostructured 3D scaffold
engineered to support soft tissue repair

BioBridge Collagen Matrix

Is intended to reinforce soft tissue
where weakness and deficiencies exist.

Download US Instructions for UseDownload International Instructions for Use
*BioBridge has not been approved by the FDA for treatment of lymphedema.
MECHANISM OF ACTION

How BioBridge works

Lymphedema is persistent swelling that develops when fluid drainage is impaired due to damage to the lymphatic vessels or lymph nodes.

Proven performance
and safety

BioBridge is manufactured from highly purified Type I porcine-derived collagen sourced from an FDA-registered and ISO-qualified supplier. Using Fibralign’s patented Nanoweave® technology, a proprietary manufacturing process produces collagen membranes with highly aligned fibrillar architecture, mimicking the mechanical properties of native extracellular matrix.

Biocompatible design

Highly purified atelocollagen minimizes immune response

Tissue integration

Designed to integrate into soft tissue safely and fully resorb

Ready to use

Provided in single-use sterile packaging

Evidence-based

Preclinical and clinical evidence validates tissue repair potential

KDA, FDA, CE and ISO certifications

Availability

BioBridge is a ready-to-use scaffold supplied in sterile single-use “5-packs” with each device stored in its own delivery tube

Find a Distributor
BioBridge Collagen Matrix five-pack
  1. Product information — BioBridge™ Collagen Matrix.
  2. Hadamitzky C. et al. Aligned nanofibrillar collagen scaffolds — guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials, 2016; 102: 259–267.
  3. Huang N. F. et al. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds. Biomaterials, 2013; 34(16): 4038–4047.
  1. Boardman K. C., Swartz M. A. Interstitial flow as a guide for lymphangiogenesis. Circulation Research, 2003; 92(7): 801–808.
  2. Lee S. O., Kim I. K. Molecular pathophysiology of secondary lymphedema. Frontiers in Cell and Developmental Biology, 2024; 12: 1363811.